For both sides
Blind teaser
Federal and state law current as of September 2026 — verify with counsel.
Key takeaways
- A one-pager that does not name the store or the owner.
- Use the term the way the regulator uses it.
- Do not import another state’s definition.
- Ask counsel before the LOI uses the word as a promise.
Blind teaser is the file this page underwrites. A one-pager that does not name the store or the owner. Federal and state law current as of September 2026 — verify with counsel. This is educational, not a guarantee of price, timing, approval, or financing.
Why Blind teaser matters in a cannabis sale — what should you verify for Blind teaser?
Owners lose months when Blind teaser is treated as slang. The application, the LOI, and the agency packet have to use one definition.
How Blind teaser is used correctly — what belongs on Blind teaser?
The correct use of Blind teaser is the one that a New Jersey reviewer would recognize. Do not import a Missouri habit unless the premises sit there.
How Blind teaser is misused — how should you read this on Blind teaser?
The usual misuse is turning blind teaser into a premium without a citation. Buyers then treat it as optional. Neither side can close on that.
| Use of Blind teaser | Broker reading |
|---|---|
| Blind teaser in a CIM | Must match the statute, not a slogan |
| Blind teaser in an LOI | If it requires agency consent, say so |
| Blind teaser in a model | Label ranges; do not hide 280E |
| Blind teaser vs a neighbor word | Do not swap blind teaser for a look-alike term from another state |
File example that turns on Blind teaser — why does this change Blind teaser?
Illustrative: a CIM inflates blind teaser into a premium. Diligence removes it. Price moves. See APA vs MIPA if the term changes who keeps the liability.
Nearby words people confuse with Blind teaser — how should you read this on Blind teaser?
If someone says blind teaser and means a different glossary entry, stop and pick the right slug. The glossary index exists so Blind teaser stays precise.
On Blind teaser, the federal overlay is a schedule split, not a national license. Federal Register 2026-08176 moved qualifying medical and FDA-approved marijuana to Schedule III on 28 April 2026. Adult-use marijuana stayed on Schedule I while a DEA hearing record sits with an administrative law judge. That is why IRC §280E still bites adult-use SG&A and why a medical slice can look different after tax.
Cited sources that govern Blind teaser: Federal Register 2026-08176 is the April 2026 medical / FDA-approved marijuana Schedule III order. IRC §280E still disallows ordinary deductions on Schedule I trafficking, which is why adult-use books stay in 280E. FinCEN FIN-2014-G001 remains the SAR frame banks actually use. SBA SOP 50 10 8 keeps plant-touching targets out of 7(a) and 504, including medical.
Related pages for Blind teaser — why does this change Blind teaser?
Read glossary index next if that file is open on Blind teaser. federal law is the companion page when Blind teaser needs that angle. Keep 280E in the working set for Blind teaser. Read deal structure next if that file is open on Blind teaser. sell is the companion page when Blind teaser needs that angle. Keep buy in the working set for Blind teaser. Read 280E next if that file is open on Blind teaser. METRC is the companion page when Blind teaser needs that angle.
Which public sources belong on this file?
Pull DEA drug scheduling, DEA diversion schedules, FDA cannabis / CBD page, IRS marijuana industry page before you price the file. A forum post is not a substitute.
Frequently asked questions
What does Blind teaser mean in a cannabis sale?
A one-pager that does not name the store or the owner.
Is this legal advice?
No. Confirm the term against the statute and counsel.
Does the definition travel across states?
No. Blind teaser in one statute is not automatically Blind teaser in another.
Where does it show up in a deal?
Applications, LOIs, CIMs, and often the approval contingency.
Sources
- Federal Register 2026-08176 (28 April 2026) — medical / FDA-approved marijuana to Schedule III — https://www.federalregister.gov/d/2026-08176
- FinCEN FIN-2014-G001 — BSA expectations for marijuana-related businesses — https://www.fincen.gov/resources/statutes-regulations/guidance/bsa-expectations-regarding-marijuana-related-businesses
- SBA SOP 50 10 8 (effective 1 June 2025) — marijuana ineligibility — https://www.sba.gov/document/sop-50-10-lender-development-company-loan-programs
- Congress.gov S.4942 — SAFE Banking Act of 2026 (introduced, not enacted) — https://www.congress.gov/bill/119th-congress/senate-bill/4942
- Congress.gov H.R.9471 — companion SAFE Banking bill — https://www.congress.gov/bill/119th-congress/house-bill/9471
- DEA drug scheduling — https://www.dea.gov/drug-information/drug-scheduling
- DEA diversion schedules — https://www.deadiversion.usdoj.gov/schedules/
- FDA cannabis and CBD page — https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
- CRS IF13136 / IN12620 — hemp definition change effective 12 November 2026 (P.L. 119-37) — https://www.congress.gov/crs-product/IN12620
- IRC §280E — https://www.law.cornell.edu/uscode/text/26/280E
- Viridian Capital public commentary — Tier 1 U.S. MSO EV/EBITDA ~4.16x (2025 consensus)